203695
bpV(phen)
A potent protein phosphotyrosine phosphatase inhibitor and insulin receptor kinase (IRK) activator.
동의어(들):
bpV(phen), Potassium Bisperoxo(1,10-phenanthroline)oxovanadate (V), PTEN Inhibitor I, PTP Inhibitor VIII
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
Linear Formula:
K[VO(O2)2C12H8N2]
CAS 번호:
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥99% (51V-NMR)
Form:
solid
Quality level:
Storage condition:
OK to freeze, protect from light
Quality Level
assay
≥99% (51V-NMR)
form
solid
potency
38 nM IC50
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
yellow
solubility
water: 5 mg/mL
shipped in
ambient
storage temp.
−20°C
SMILES string
[V]=O.[K+].n1c2c3ncccc3ccc2ccc1.OO.OO
InChI
1S/C12H8N2.K.2H2O2.O.V/c1-3-9-5-6-10-4-2-8-14-12(10)11(9)13-7-1;;2*1-2;;/h1-8H;;2*1-2H;;/q;+1;;;;
InChI key
MQPXOTNOFVCXDA-UHFFFAOYSA-N
General description
A potent insulin receptor kinase (IRK) activator and protein phosphotyrosine phosphatase inhibitor. Excellent insulin mimetic for in vitro and in vivo use (15 µg/kg). Inhibits in situ dephosphorylation of autophosphorylated insulin receptors with greater than 1000-fold potency over sodium orthovanadate. Arrests proliferation of neuroblastoma NB 41 and glioma C6 cells at the G2/M transition of the cell cycle. Also reported to potently inhibit PTEN (IC50 = 38 nM). The water content varies from lot to lot and is supplied on the label along with the lot-specific molecular weight.
A potent protein phosphotyrosine phosphatase inhibitor and insulin receptor kinase (IRK) activator. Excellent insulin mimetic at 15 µg/kg in vitro and in vivo for use. Inhibits the in situ dephosphorylation of autophosphorylated insulin receptors with over 1000-fold greater potency than sodium orthovanadate. Arrests proliferation of neuroblastoma NB 41 and glioma C6 cells at the G2/M transition of the cell cycle. Also reported to potently inhibit PTEN (IC50 = 38 nM).
The water content varies from lot to lot and is supplied on the label along with the lot-specific molecular weight.
Biochem/physiol Actions
Product does not compete with ATP.
Reversible: no
Cell permeable: no
Primary Target
PTEN
PTEN
Packaging
Packaged under inert gas
Preparation Note
Unstable in solution; reconstitute just prior to use.
Other Notes
Schmid, A.C., et al. 2004. FEBS Lett.566, 35.
Muzyamba, M.C., et al. 1999. J. Physiol. 517, 421.
Drake, P.G., et al. 1996. Endocrinology137, 4960.
Bevan, A.P., et al. 1995. Am. J. Physiol.268, E60.
Bevan, A.P., et al. 1995. J. Biol. Chem. 270, 10784.
Yale, J.F., et al. 1995. Diabetes 44, 1274.
Posner, B.I., et al. 1994. J. Biol. Chem. 269, 4596.
Muzyamba, M.C., et al. 1999. J. Physiol. 517, 421.
Drake, P.G., et al. 1996. Endocrinology137, 4960.
Bevan, A.P., et al. 1995. Am. J. Physiol.268, E60.
Bevan, A.P., et al. 1995. J. Biol. Chem. 270, 10784.
Yale, J.F., et al. 1995. Diabetes 44, 1274.
Posner, B.I., et al. 1994. J. Biol. Chem. 269, 4596.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
저장 등급
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
Sameer S Chopra et al.
Cell systems, 10(1), 66-81 (2019-12-10)
Frequent mutation of PI3K/AKT/mTOR signaling pathway genes in human cancers has stimulated large investments in targeted drugs but clinical successes are rare. As a result, many cancers with high PI3K pathway activity, such as triple-negative breast cancer (TNBC), are treated
국제 무역 품목 번호
| SKU | GTIN |
|---|---|
| 203695-10MGCN | 07790788048365 |